CTOs on the Move

Texas Original Compassionate Cultivation

www.texasoriginal.com

 
Our mission is to create the highest quality medicine that changes people’s lives. We stand beside all who believe in safe, legal and effective access to this powerful medicine. As fellow Texans, we see this as our responsibility to take care of our neighbors.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Texas Original Compassionate Cultivation raised $21M on 06/07/2021

Similar Companies

NotCo

Same taste, but plant-based. A food revolution has started. Know the future of food. Why not?

Seisa Medical

Seisa Medical is a El Paso, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Omniome

Based in San Diego and founded in 2013, Omniome is a biotechnology company developing a proprietary DNA sequencing platform capable of delivering unsurpassed sequencing accuracy. Backed by leading life sciences venture investors and a proven management team, Omniome`s vision is to be the most trusted DNA sequencing platform and leader in clinical sequencing. We are a quality-focused, start-up environment where development thrives. Our culture is inspiring, fun and consists of a talented team of individuals who propose innovative ideas keeping collaboration a top priority.

Simplex Sciences

High quality, reliable single-stranded DNA ladders from Simplex Sciences. 10, 20, 50, and 100 base increment ladders are available, with new products coming soon.

Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum`s proprietary product engine, FulcrumSeek™, identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia into Phase 1 clinical development.